LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lyell Immunopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.80+0.68 (+8.37%)
Close on Oct 19, 2026
- Market cap
- $205.60M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-748344.4%−745611.9 pts over 5 years
Net margin
-762355.6%−759719.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -41.0% | -92.5% | -65.9% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 101.3% | -87.0% | |
| Return on assets | – | – | -66.1% | |
| Current ratio | – | 12.53 | 5.28 | |
| Capex to revenue | – | 663.8% | 2166.7% | |
| Diluted shares | – | 1M | 17M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lyell Immunopharma generated $771.92M from operations and spent $93.71M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$771.92M
Used
$93.71M
Capital expenditure$93.71M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-762355.6%
×Asset turnover0.00×
×Equity multiplier1.32×
=Return on equity, FY2025-87.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -762355.6% | 0.00× | 1.32× | -87.0% |
| FY2024 | -562285.2% | 0.00× | 1.20× | -66.1% |
| FY2023 | -180486.2% | 0.00× | 1.13× | -31.5% |
| FY2022 | -216.2% | 0.08× | 1.17× | -20.8% |
| FY2021 | -2349.5% | 0.01× | 3.19× | -78.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$274.45M
- Cash generatingOperating cash flow above zero-$150.02M
- Return on assets improvedROA up on the prior year-45.7% → -55.9%
- Earnings backed by cashOperating cash flow above net income-$150.02M vs -$274.45M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.06 → 5.28
- No dilutionShare count did not rise13M → 17M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00